Lecigon

Entacapone/Levodopa/Carbidopa, the active ingredient in Lecigon, is a combination dopamine precursor and COMT inhibitor presented as an oral tablet for intestinal use. It is prescribed to manage Parkinson's disease symptoms in adults, particularly those with motor fluctuations, by enhancing central dopamine availability.

GNH USA supplies Lecigon as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets while adhering to stringent quality and regulatory standards, including compliance with EU pharmacopeial specifications and reliable delivery timelines.

Lecigon, a combination antiparkinson agent, is used in the management of Parkinson's disease as part of levodopa‑based therapy.

- Parkinson's disease (early or advanced): improves motor control and reduces OFF periods. - Motor fluctuations in Parkinson's disease: prolongs the effect of levodopa, decreasing dosing frequency. - Adjunct to levodopa therapy: enhances central dopamine levels, allowing better symptom control.

Lecigon may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools often occurring early in therapy. - Dyskinesia: involuntary movements due to increased dopamine. - Orthostatic hypotension: dizziness upon standing.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe neutropenia: marked reduction in white blood cells. - Neuroleptic malignant‑like syndrome: high fever, muscle rigidity, altered mental status.

When prescribing Lecigon, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust therapy and monitor renal function. - Hepatic disease: use with caution; assess liver enzymes regularly. - Cardiovascular disorders: monitor blood pressure due to orthostatic effects. - Concomitant MAO‑B inhibitors: avoid simultaneous use to prevent hypertensive crisis. - Pregnancy and lactation: safety not established; weigh risks versus benefits. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Lecigon can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Anticholinergic agents: may exacerbate cognitive side effects. - CNS depressants (e.g., opioids, benzodiazepines): increase sedation and dizziness.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: orthostatic hypotension may be enhanced. - Iron or calcium supplements: reduce levodopa absorption; separate dosing by at least 2 hours. - SSRIs or SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibition.